CN1202127C - 癌症治疗中的免疫刺激剂细菌膜组分 - Google Patents

癌症治疗中的免疫刺激剂细菌膜组分 Download PDF

Info

Publication number
CN1202127C
CN1202127C CNB008050503A CN00805050A CN1202127C CN 1202127 C CN1202127 C CN 1202127C CN B008050503 A CNB008050503 A CN B008050503A CN 00805050 A CN00805050 A CN 00805050A CN 1202127 C CN1202127 C CN 1202127C
Authority
CN
China
Prior art keywords
purposes
precipitation
membrane component
pharmaceutical composition
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008050503A
Other languages
English (en)
Chinese (zh)
Other versions
CN1343125A (zh
Inventor
C·里邦
N·科瓦伊亚
A·贝克
J－Y·邦尼福伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN1343125A publication Critical patent/CN1343125A/zh
Application granted granted Critical
Publication of CN1202127C publication Critical patent/CN1202127C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CNB008050503A 1999-03-15 2000-03-15 癌症治疗中的免疫刺激剂细菌膜组分 Expired - Fee Related CN1202127C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903154A FR2790960B1 (fr) 1999-03-15 1999-03-15 Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
FR99/03154 1999-03-15

Publications (2)

Publication Number Publication Date
CN1343125A CN1343125A (zh) 2002-04-03
CN1202127C true CN1202127C (zh) 2005-05-18

Family

ID=9543185

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008050503A Expired - Fee Related CN1202127C (zh) 1999-03-15 2000-03-15 癌症治疗中的免疫刺激剂细菌膜组分

Country Status (14)

Country Link
US (1) US7033591B1 (https=)
EP (1) EP1161250B9 (https=)
JP (1) JP2002539170A (https=)
CN (1) CN1202127C (https=)
AT (1) ATE302014T1 (https=)
AU (1) AU776350B2 (https=)
BR (1) BR0009052A (https=)
CA (1) CA2367211A1 (https=)
DE (1) DE60022011T2 (https=)
DK (1) DK1161250T3 (https=)
ES (1) ES2246831T3 (https=)
FR (1) FR2790960B1 (https=)
WO (1) WO2000054790A1 (https=)
ZA (1) ZA200107368B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2808445A1 (fr) * 2000-05-04 2001-11-09 Pf Medicament Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues
FR2809014A1 (fr) * 2000-05-16 2001-11-23 Pf Medicament Utilisation d'une proteine ompa d'enterobacterie comme agent antimicrobien
GB2370838A (en) * 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
FR2822071B1 (fr) * 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
EP4241853B1 (en) * 2013-11-26 2026-02-11 Zoetis Services LLC Compositions for induction of immune response
GB201713975D0 (en) * 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CN113727722A (zh) * 2019-02-22 2021-11-30 伊夫罗生物科学公司 细菌膜制剂
EP4190894A1 (en) 2021-12-03 2023-06-07 CiMaas B.V. Method for the production of mature dendritic cells in vitro using a bacterial lysate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471785A1 (fr) * 1979-12-21 1981-06-26 Fabre Sa Pierre Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn
FR2523154A1 (fr) * 1982-03-09 1983-09-16 Fabre Sa Pierre Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant
FR2596064B1 (fr) * 1986-03-18 1990-02-02 Pf Medicament Procedes industriels de fabrication de vaccins ribosomaux et vaccins ribosomaux obtenus
AU603585B2 (en) * 1986-05-07 1990-11-22 Sloan-Kettering Institute For Cancer Research Vaccine for stimulating or enhancing production of antibodies directed against GM2
AU7477791A (en) * 1990-03-02 1991-09-18 Joaquin J. Jimenez Method for treating cancer using combination chemotherapy and brm
US5242806A (en) * 1990-05-07 1993-09-07 Baxter Diagnostics Inc. Method for conducting the cytotoxicity assays on tumor cells
US5776898A (en) * 1991-05-14 1998-07-07 Dana-Farber Cancer Institute Method for treating a tumor with a chemotherapeutic agent
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
FR2785542B1 (fr) * 1998-11-06 2001-02-09 Pf Medicament UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES

Also Published As

Publication number Publication date
CN1343125A (zh) 2002-04-03
AU3298100A (en) 2000-10-04
EP1161250B1 (fr) 2005-08-17
EP1161250B9 (fr) 2006-07-05
JP2002539170A (ja) 2002-11-19
DE60022011T2 (de) 2006-06-14
FR2790960B1 (fr) 2002-10-31
DE60022011D1 (de) 2005-09-22
BR0009052A (pt) 2001-12-26
US7033591B1 (en) 2006-04-25
ATE302014T1 (de) 2005-09-15
WO2000054790A1 (fr) 2000-09-21
CA2367211A1 (fr) 2000-09-21
FR2790960A1 (fr) 2000-09-22
AU776350B2 (en) 2004-09-02
EP1161250A1 (fr) 2001-12-12
ES2246831T3 (es) 2006-03-01
ZA200107368B (en) 2002-06-26
DK1161250T3 (da) 2005-12-12

Similar Documents

Publication Publication Date Title
CN1250285C (zh) 被称作胞外体的细胞囊泡,其制备方法及在免疫刺激中的用途
CN1178956C (zh) 基于癌抑制基因wt1的产物的癌抗原
CN1184320C (zh) Mhc－ⅱ类配体作为疫苗佐剂以及lag－3用于癌症治疗的应用
CN1237909A (zh) 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗
CN1194000A (zh) 增强保护性免疫应答的方法
CN1520311A (zh) 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
CN1202127C (zh) 癌症治疗中的免疫刺激剂细菌膜组分
CN1281748C (zh) 为改善IL－12活性而突变的IL－12p40亚基基因及其作为DNA疫苗佐剂的用途
CN1079166A (zh) 用白细胞介素-10抑制移植物抗宿主病
CN1705747A (zh) 抗hpv疫苗的载体以及该载体转化的微生物
CN1656116A (zh) 包含hpv－16病毒的突变e7蛋白的非免疫抑制免疫原性组合物或疫苗组合物
CN1718243A (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
CN1181890C (zh) 肠细菌OmpA蛋白在制备特异导向抗原呈递细胞的药物中的应用
CN1956727A (zh) 诱导抗金黄色葡萄球菌的保护性免疫应答的多肽
CN101048178A (zh) 作为疫苗的重组分枝杆菌和生物活性剂的组合
CN101080420A (zh) 胸腺特异性蛋白质
CN1639569A (zh) 诱导免疫应答的方法和组合物
CN1810970A (zh) 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
CN1335889A (zh) 编码l.infantum的四种蛋白质的抗原决定簇的嵌合基因
CN1910284A (zh) 由HLA－A2402－限制的Ep－CAM－特异的CTL识别的表位/肽及其应用
CN1929855A (zh) 诱导或调节免疫反应的方法
CN1151799C (zh) 具有佐剂作用的细菌膜组分
CN1727362A (zh) 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
CN1807452A (zh) 幽门螺杆菌尿素酶B亚单位的Th表位肽、其编码DNA、疫苗及其应用
CN1775802A (zh) 人类乳头瘤病毒免疫原性多肽、其制备方法及应用

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050518

Termination date: 20110315